Lead Product(s) : Treosulfan
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Technische Universität Dresden
Deal Size : Inapplicable
Deal Type : Inapplicable
Treosulfan Vs Melphalan Conditioning + PTCy In AML/MDS Allogeneic Transplant
Details : Treosulfan is a Cytotoxic Drug drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
June 18, 2025
Lead Product(s) : Treosulfan
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Technische Universität Dresden
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treosulfan,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Strategic cornerstone: FDA approves treosulfan for alloHSCT
Details : Grafapex (treosulfan) is now approved by FDA for the treatment of adult and pediatric patients aged 1 year and older with acute myeloid leukemia.
Product Name : Grafapex
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
January 23, 2025
Lead Product(s) : Treosulfan,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treosulfan
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Medexus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Medexus and medac Conclude Negotiations to Amend US Treosulfan Agreement
Details : The fourth amendment adjusts the unpaid regulatory milestone payments upon an FDA approval of Grafapex (treosulfan).
Product Name : Grafapex
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
December 02, 2024
Lead Product(s) : Treosulfan
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Medexus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Methotrexate
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.
Details : Methotrexate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 02, 2024
Lead Product(s) : Methotrexate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mitomycin
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : UroGen Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
UroGen gets Medac License to Develop Novel Mitomycin Formulation for Urothelial Cancers
Details : Under the agreement, UroGen will develop a next-generation novel mitomycin-based formulation, UGN-103, UroGen’s RTGel® technology combined with medac’s licensed mitomycin, for urothelial cancers.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
January 17, 2024
Lead Product(s) : Mitomycin
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : UroGen Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : MC0518
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MC0518 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Graft vs Host Disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 10, 2023
Lead Product(s) : MC0518
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methotrexate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Eisai
Deal Size : Inapplicable
Deal Type : Inapplicable
Metoject® Subcutaneous Injection Syringe (Methotrexate) Approved in Japan for Rheumatoid Arthritis
Details : Primary endpoint of ACR20 response* at 12 weeks was 59.6% in Metoject (Methotrexate) group versus 51.0% in oral MTX group, indicating comparable efficacy. Adverse drug reaction incidence rates in this trial were 25.0% in the Metoject group and 34.0% in t...
Product Name : Metoject
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
September 26, 2022
Lead Product(s) : Methotrexate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Eisai
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treosulfan,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Medexus Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Medexus Provides Update on Treosulfan NDA Resubmission and Provides Business Update
Details : Trecondyv (treosulfan) is used to prepare patients for blood stem cell transplant. Trecondyv destroys bone marrow cells. This allows for the transplant of new blood stem cells from a donor which leads to the production of healthy blood cells.
Product Name : Trecondyv
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
September 19, 2022
Lead Product(s) : Treosulfan,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Medexus Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treosulfan
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
Details : Treosulfan is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
September 09, 2022
Lead Product(s) : Treosulfan
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : oNKord,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Glycostem Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, medac receives an exclusive license to commercialize oNKord® (GTA002) in the EU, the UK and further European countries for acute myeloid leukemia (AML) and multiple myeloma (MM) patients.
Product Name : oNKord
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
August 01, 2022
Lead Product(s) : oNKord,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Glycostem Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
KEY SERVICES
Reset All
medac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.
